Buloxibutid is under clinical development by Vicore Pharma and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Buloxibutid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Buloxibutid overview

Buloxibutid (VP-01) is under development for the treatment of idiopathic pulmonary fibrosis and pulmonary arterial hypertension (PAH). It is administered through oral and intravenous route. The drug candidate is a small non-peptide. It is highly selective for the angiotensin II receptor type-2 (AT2) receptor. The drug is based on a receptor targeting technology which includes molecules with agonistic action to the AT2 receptor. It was under development for the treatment of coronavirus disease 2019 (COVID-19).

Vicore Pharma overview

Vicore Pharma formerly Pharmacore, a subsidiary of Vicore Pharma Holding AB, operates as a biotechnology company focused on the development of orphan drugs for the treatment of fibrotic diseases. Its lead product candidate C21 that stimulates the AT2 receptors is used for the treatment of idiopathic pulmonary fibrosis (IPF). Its portfolio includes small molecules with potential indications which are used in various therapeutic indications such as anti-inflammation, neuro protection, neuro regeneration, and cardiovascular diseases. The company seeks to work in collaboration with pharmaceutical companies to accelerate the development and licensing opportunities for its pipeline products. Vicore Pharma is headquartered in Molndal, Sweden.

For a complete picture of Buloxibutid’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.